scholarly journals Should Antiarrhythmic Treatment Be Considered Doping in a Shooting Athlete?

2021 ◽  
Vol 34 (1) ◽  
pp. 28-31
Author(s):  
Renata Rodrigues Teixeira de Castro
Keyword(s):  
Antiarrhythmic Treatment

Effect of Prenatal Antiarrhythmic Treatment on Cardiac Function in a Twin Pregnancy

2008 ◽  
Vol 31 (9) ◽  
pp. 1213-1217 ◽  
Author(s):  
PETER VAN LEEUWEN ◽  
SVEN SCHIERMEIER ◽  
BIRGIT HAILER ◽  
SILKE LANGE ◽  
DANIEL GEUE ◽  
...  
Keyword(s):  
Cardiac Function ◽  
Twin Pregnancy ◽  
Antiarrhythmic Treatment

The Possible Relevance of Late Potentials for the Identification of Patients Needing Antiarrhythmic Treatment

1983 ◽  
pp. 37-52 ◽  
Author(s):  
G. Breithardt ◽  
M. Borggrefe ◽  
U. Karbenn ◽  
K. Haerten ◽  
J. Ostermeyer ◽  
...  
Keyword(s):  
Late Potentials ◽  
Antiarrhythmic Treatment

P6248High use of direct oral anticoagulants in elderly patients with non valvular atrial fibrillation: results of REFLEJA study

2019 ◽  
Vol 40 (Supplement_1) ◽  
Author(s):  
J Torres Llergo ◽  
M R Fernandez Olmo ◽  
M Carrillo Bailen ◽  
M Puentes Chiachio ◽  
M Martin Toro ◽  
...  
Keyword(s):  
Atrial Fibrillation ◽  
Older Patients ◽  
Oral Anticoagulants ◽  
Direct Oral Anticoagulants ◽  
P Value ◽  
Hemorrhagic Risk ◽  
Independent Risk Factors ◽  
Artery Disease ◽  
Anticoagulated Patients ◽  
Antiarrhythmic Treatment

Abstract Background Older patients with atrial fibrillation (AF) have a higher thromboembolic and hemorrhagic risk, however oral anticoagulation (OAC) continues to be underutilized. Purpose To analyze the use of direct oral anticoagulant (DOAC) in patients older than 80 years. Methods The REFLEJA study is a single-centre prospective observational registry including 1039 consecutive outpatients with nonvalvular AF. Results Among ≥80 years patients (n=376) there were more women (57.7% vs 41.5%; p<0.001), permanent AF (66.5 vs 42%; <0.001), heart failure (HF) (29.8 vs 20.2%, p<0.001) and vascular disease (19.7 vs 12.8%, p=0.003), although without differences in bleeding (5.9 vs 3,8%, p=0.12) and previous strokes (9.3 vs 7.1%, p=0.20). Despite a higher CHA2DS2-VASc score (4.4±1.1 VS 2.9±1.6, p<0.001), HASBLED score >2 (34.6 vs. 23.7%; p<0.001) and chronic kidney disease (CKD) (51.5 vs. 22.6%, p<0.001), total use of OAC was higher among those older (94.9% vs 90%, p=0.005). There were no differences in the prescription of DOAC (64.1% vs 69.3%, p=0.08), although lower doses (45.8 vs. 12.2%, p<0.005) were more frecuent among older patients. In multivariate analysis, HF (OR 0.60, CI 0.40–0.90; p=0.013) and CKD (OR 0.55, CI 0.41–0.76; p<0.001) were independent risk factors for the prescription of DOAC, but not age ≥80 years (OR 1.16, CI 0.58–2.31, P=0.67). Baseline characteristics Total <80 years ≥80 years p value Hypertension (%) 81.5 77.9 88 <0.001 Diabetes mellitus (%) 26.3 25.7 26.7 0.71 Malignancy (%) 6.6 6.5 6.9 0.78 Coronary artery disease (%) 12.1 10.8 14.4 0.08 Anemia (%) 16.3 12.5 23.2 <0.001 DOAC (%) 67.6 69.3 64.1 0.08 Low doses DOAC (%) 15.9 12.2 45.8 <0.001 CHA2DS2-VASc score 3.4±1.6 2.9±1.6 4.4±1.1 <0.001 HAS-BLED score 1.2±0.8 1.1±0.8 1.4±0.7 <0.001 Glomerular filtration rate (ml/min) 70.9±24.9 76.2±23.1 61.5±25 <0.001 Antiarrhythmic treatment (%) 7.3 9.6 3.1 0.005 Permanent AF 50.5 41.7 66.2 <0.001 DOAC: direct oral anticoagulants; HAS-BLED score: without INR lability; AF: atrial fibrillation. Conclusion The proportion of elderly anticoagulated patients in our environment is very high and advanced age was not associated with a lower use of DOAC.

scholarly journals Drug Resistant Fetal Arrhythmia in Obstetric Cholestasis

2015 ◽  
Vol 2015 ◽  
pp. 1-4
Author(s):  
Nahide Altug ◽  
Ayse Kirbas ◽  
Korkut Daglar ◽  
Ebru Biberoglu ◽  
Dilek Uygur ◽  
...  
Keyword(s):  
Liver Disease ◽  
Bile Acid ◽  
Supraventricular Tachycardia ◽  
Preterm Labor ◽  
Fetal Distress ◽  
Intrauterine Death ◽  
Drug Resistant ◽  
Fetal Arrhythmia ◽  
Antiarrhythmic Treatment

Obstetric cholestasis (OC) is a pregnancy specific liver disease characterized by increased levels of bile acid (BA) and pruritus. Raised maternal BA levels could be associated with intrauterine death, fetal distress, and preterm labor and also alter the rate and rhythm of cardiomyocyte contraction and may cause fetal arrhythmic events. We report a case of drug resistant fetal supraventricular tachycardia and concomitant OC.Conclusion.If there are maternal OC and concomitant fetal arrhythmia, possibility of the resistance to antiarrhythmic treatment should be kept in mind.

scholarly journals Fetal Atrial Flutter and Hydrops Successfully Treated with Transplacental and Direct Fetal Therapy

2016 ◽  
Vol 6 (1) ◽  
pp. 16-21
Author(s):  
Bettina F. Cuneo
Keyword(s):  
Sinus Rhythm ◽  
Atrial Flutter ◽  
Marked Change ◽  
Postnatal Life ◽  
Fetal Therapy ◽  
Fetal Ultrasound ◽  
Fetal Demise ◽  
Antiarrhythmic Medications ◽  
Antiarrhythmic Treatment

AbstractThe hydropic fetus with atrial flutter has high risk of fetal demise. In utero treatment is not as successful as SVT with 1:1 conduction. Even after conversion to sinus rhythm, close follow-up of the pregnancy is required for several reasons..Case Report:A 25 year old primigravida, at 26 wks of gestation had a fetal ultrasound which showed a tachycardic hydropic fetus with AFI 49. The rhythm was atrial flutter: AR 400 bpm and VR 200 bpm. The heart was structurally normal. Transplacental antiarrhythmic treatment with sotalol was started and 24 hours later, the fetus was still primarily in flutter with rare episodes of sinus rhythm and frequent PAC. Sotalol was increased but the mother’s QTc increased to > 500 ms, so the sotalol dose was reduced. On day 4th direct i.m. of digoxin was given and fetus was in sinus rhythm. Pharmacotherapy was continued. On the 16th day of sinus rhythm (at 33 wks), a marked change in FHR variability was seen. An US revealed the fetus was in sinus rhythm with a normal FHR. Because of the decreased FHR variability, the fetus was delivered by CS and the cord pH was 7.19, Apgars 1, 9 and 9. The neonate received no antiarrhythmic medications. On day 6 of postnatal life, an AV re-entrant tachycardia (AVRT) developed and sinus rhythm was successfully restored with sotalol and digoxin. The infant was treated for 18 months with no episodes of SVT or atrial flutter.

scholarly journals Classification of persistent and long-standing persistent atrial fibrillation by means of surface electrocardiograms

2016 ◽  
Vol 61 (1) ◽  
pp. 19-27 ◽  
Author(s):  
Nuria Ortigosa ◽  
Carmen Fernández ◽  
Antonio Galbis ◽  
Óscar Cano
Keyword(s):  
Atrial Fibrillation ◽  
Population Sample ◽  
Structural Heart Disease ◽  
Persistent Atrial Fibrillation ◽  
Time Frequency ◽  
Tertiary Center ◽  
History Of ◽  
Novel Method ◽  
Antiarrhythmic Treatment

Abstract Atrial fibrillation, which is the most common cardiac arrhythmia, is typically classified into four clinical subtypes: paroxysmal, persistent, long-standing persistent and permanent. The ability to distinguish between them is of crucial significance in choosing the most suitable therapy for each patient. Nevertheless, classification is currently established once the natural history of the arrhythmia has been disclosed as it is not possible to make an early differentiation. This paper presents a novel method to discriminate persistent and long-standing atrial fibrillation patients by means of a time-frequency analysis of the surface electrocardiogram. Classification results provide approximately 75% accuracy when evaluating ECGs of consecutive unselected patients from a tertiary center and higher than 80% when patients are not under antiarrhythmic treatment or do not have structural heart disease (76% sensitivity and 88% specificity). Moreover, to our knowledge, this is the first study that discriminates between persistent and long-standing persistent subtypes in a heterogeneous population sample and without discontinuing antiarrhythmic therapy to patients. Thus, it can help clinicians to address the most suitable therapeutic approach for each patient.

scholarly journals Triggering atrial fibrillation after omalizumab injection in a patient with chronic spontaneous urticarial. A case report

2019 ◽  
Vol 92 (1) ◽  
pp. 91-93 ◽  
Author(s):  
Songul Cildag
Keyword(s):  
Atrial Fibrillation ◽  
Side Effects ◽  
Chronic Spontaneous Urticaria ◽  
Line Treatment ◽  
Efficacy And Safety ◽  
High Efficacy ◽  
Biological Treatments ◽  
Third Line ◽  
Antiarrhythmic Treatment ◽  
Third Line Treatment

Introduction. Omalizumab is recommended as a third-line treatment in the treatment of chronic spontaneous urticaria. During omalizumab use, which has high efficacy and safety, the side effects observed are usually moderate and temporary. Here we discuss the triggering of atrial fibrillation following omalizumab injection.Case report. A 72-year-old female patient was treated with omalizumab 300 mg / day due to chronic spontaneous urticaria resistant to conventional treatments. Atrial fibrillation developed 6 hours after the second injection of omalizumab in the patient who had atrial fibrillation and who had been monitored with antiarrhythmic treatment and sinus rhythm for 1 year. The treatment was discontinued because omalizumab was thought to trigger atrial fibrillation, as no other reason to explain the triggering of atrial fibrillation could be found.Results and conclusion. There is no data in the literature on the use of omalizumab in patients with atrial fibrillation. Different side effects of biological treatments can be observed. In particular, omalizumab should be used with caution in elderly patients and patients with arrhythmia.

Sign in / Sign up

Export Citation Format

Share Document